In recent years, 68Ga-PSMA-11 PET/CT has gained increasing importance in the management of prostate cancer for initial staging [15], biochemical recurrence [16], detection of metastases in non-metastatic CRPC [17], and screening for 177Lu-PSMA-617 RLT. This evidence concerns the gene FOLH1 and prostate cancer.